FOI Request
- Disclosure ID
- FOI 02596
- Request Date
- July 27, 2018
- Subject
- AMD Eye Injections Implants
- Description
Within your trust how many patients have been treated, in the past 6 months January to June 2018 by diagnosed eye condition. Of these patients how many are new to treatment [they have not previously received an injection / implant]? If your trust can not split by condition, please supply the total patients and total new patients. A new patient is one that has not previously received an injection in either eye for an ophthalmology condition.
Total Patients New Patients Lucentis (ranibizumab) Patients Lucentis (ranibizumab) NEW Patients Eylea (aflibercept) Patients Eylea (aflibercept) NEW Patients Other Patients (bevacizumab, Dexamathasone or Fluocinolone) Other NEW Patients (bevacizumab, Dexamathasone or Fluocinolone) Total Wet Age Related Macular Degeneration (wAMD) Other conditions (DMO, RVO or mCNV) If you do not have full records an estimate would be helpful.
- Response
Total Wet Age Related Macular Degeneration (wAMD, RVO or mCNV) Other conditions (DMO) Total Patients 3059 2397 662 New Patients We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)). Lucentis (ranibizumab) Patients 486 347 Lucentis (ranibizumab) NEW Patients
We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
Eylea (aflibercept) Patients 1911 315 Eylea (aflibercept) NEW Patients We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)). Other Patients (bevacizumab, Dexamathasone or Fluocinolone 0 0 Other NEW Patients (bevacizumab, Dexamathasone or Fluocinolone) We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).